

## DAFTAR PUSTAKA

1. Shree V , Vithya , et al. A Study on Blood and Blood Components Transfusion. Adverse Reaction at a Tertiary Care Teaching Hospital, Bangalore. *J Blood Disord Transfus.* 2016; 7(6):2-4
2. Haroen H. Darah dan Komponen : Komposisi, Indikasi dan Cara Pemberian. Buku Ajar Ilmu Penyakit Dalam. Ed VI.Jakarta: Interna Publishing; 2014.p2847-2853
3. Lubart E, Segal R, et al. Blood transfusion reactions in elderly patients hospitalized in a multilevel geriatric hospital. *J Ageing Res.* 2014;2014:3.
4. Vartak UC , Shewale R, et al. Adverse Reactions of Blood Transfusion: A Study in a Tertiary Care Hospital . *International Journal of Scientific Study* . 2016; 4(2):90
5. Sahu S, Hemlata, et al. Adverse events related to blood transfusion. *Indian J Anaesth.* 2014;58:543–551.
6. Delaney M, Wendel S, et al. Transfusion reactions:prevention, diagnosis, and treatment. *Lancet.* 2016;388:2825–2836.
7. WHO. The clinical use of blood: handbook. Geneva, 2002. Didapat dari URL: [http://www.who.int/bct/Main\\_areas\\_of\\_work/Resource\\_Centre/CUB/English/Handbook.pdf](http://www.who.int/bct/Main_areas_of_work/Resource_Centre/CUB/English/Handbook.pdf).
8. Harvey AR, Basavaraju SV, Chung KW, et al. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012. *Transfusion* 2015;55(4):709–18.
9. Wahidiyat PA, Marpaung E, et al. Characteristics of acute transfusion reactions and its related factors in Cipto Mangunkusumo Hospital Jakarta, Indonesia. *Health Sci J Indones.* 2019;10(1):15-20.
10. Borhany M, Anwar N, et al. Acute blood transfusion reactions in a tertiary care hospital in Pakistan - an initiative towards haemovigilance. *Transfus Med.* 2019;29(4):275-8.
11. Payung, Rachmawati, et al. Factors in Acute Transfusion Reaction. *Indones.J.Clin. Pathol.Med.Lab.*2016 July; 22(3): 274–278

12. Djoerban Z. Dasar dasar Transfusi Darah. Buku Ajar Ilmu Penyakit Dalam. Ed VI. Jakarta: Interna Publishing; 2014.p2842-2843
13. Mulyantari NK , Yasa IWPS. Uji Cocok Serasi. Laboratorium Pratreansfusi Update. Udayana University Press. 2017. P86-87
14. Singhal M, Patel M, et al. A research analysis on blood component usage and wastage in blood bank and blood component center. *J. Physiol.* 2013 ; 23-28
15. Ranganathan S, Sesikeran S, et al. Emergency therapeutic leukapheresis in a case of acute myeloid leukemia M5. *Asian J. Transfus.* 2008; 2(1):18-19.
16. J. L. Carson, B. J. Grossman, and S. Kleinman, "Red blood cell transfusion: a clinical practice guideline from the AABB. *An Int Med.* 2008; 49–58, 2012.
17. P. H. B. Bolton-Maggs, "SHOT conference report: serious hazards of transfusion – human factors continue to cause most transfusion-related incidents," *Trans Med.* 2016; 26(6), pp. 401–405.
18. Menis M, Forshee RA, et al. Febrile non-haemolytic transfusion reaction occurrence and potential risk factors among the U.S. elderly transfused in the inpatient setting, as recorded in Medicare databases during 2011-2012. *Vox Sang*, 2015;108(3):251–61.
19. Popovsky MA, Robillard P, et al. ISBT Working Party on Haemovigilance. Proposed standard definitions for surveillance of noninfectious adverse transfusion reactions. 2011. Available from: <http://www.ihn-org.com/wp-content/uploads/2011/06/ISBT-definitions-for-non-infectious-transfusion-reactions.pdf>. [Last accessed on 2014 Jun 15].
20. CDC. NHSN Biovigilance Component, Hemovigilance Module Surveillance Protocol v2.1.3. Atlanta: Centers for Disease Control and Prevention, 2014.
21. Harmono TM. Pencegahan dan Penanganan Komplikasi Transfusi Darah. Buku Ajar Ilmu Penyakit Dalam. Ed VI. Jakarta: Interna Publishing; 2014.p2854-2860
22. Michelis FV, Branch DR, et al. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes. *Transfusion.* 2014;54(3):681-690.
23. Fung M, Grossman BJ, et al. Technical Manual, 18th edn. Glen Burnie, MD: AABB Press, 2014.

24. US Food and Drug Administration. Transfusion/donation fatalities. <http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/24> Cancer Control TransfusionDonationFatalities. Accessed November 5, 2014.
25. Huh YO, Lichtiger B. Transfusion reactions in patients with cancer. *Am J Clin Path.* 1987;87(2):253-257.
26. Tinegate H, Birchall J, et al; BCSH Blood Transfusion Task Force. Guideline on the investigation and management of acute transfusion reactions. *Br J Haematol.* 2012;159(2):143-153.
27. Heddle NM, Blajchman MA, et al. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. *Transfusion* 2002; 42(5):556–66.
28. Lin JS, Tzeng CH, et al. Cytokine release in febrile non-haemolytic red cell transfusion reactions. *Vox Sang* 2002; 82(3): 156–60.
29. Dalton J, Adamu A. Acute Transfusion Reactions: Management and Investigation. *Nur Heal Sci J.* 2015
30. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2012. <http://www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm346639.htm#A> (accessed 24/06/2014).
31. Domen RE, Hoeltge GA. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. *Arc Path Lab Med* 2003; 127: 316–20
32. Sahu A, Bajpai M. Determining The True Incidence of Acute Transfusion Reactions : Active Surveillance at A Specialized Liver Center. *Hem Tran Cell Ther.* 2020; 42(4): 326-332
33. Matsuyama N, Hirayama F, et al. Application of the basophil activation test in the analysis of allergic transfusion reactions. *Trans Med* 2009; 19: 274–7.
34. Squires JE. Risks of Transfusion. *SMJ.* 2011; (104): 762-769
35. Guideline on the investigation and management of acute transfusion reactions. *Br J Haematol.* 2012;159(2):143-153.

36. Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. *Br J Haematol.* 2013;160(4):434-444.
37. Zilberstein J, McCurdy MT, et al. Anaphylaxis. *J Emerg Med.* 2014;47(2):182-187.
38. Kleinman S, Caulfield T, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. *Transfusion.* 2004;44(12):1774-1789.
39. Toy P, Popovsky MA, et al. Transfusion-related acute lung injury: definition and review. *Crit Care Med.* 2005;33(4):721-72
40. Kopko P, Marshall C, et al. Transfusion Related Acute Lung Injury. Report of A Clinical Look Back Investigation. *J Am Med As.* 2002;287(15): 1968-1971
41. Finlayson J, Grey D, et al. Transfusion-related acute lung injury in a neutropenic patient. *Intern Med J.* 2011;41(8):638-641.
42. Andrzejewski C Jr, Casey MA, Popovsky MA. How we view and approach transfusion-associated circulatory overload: pathogenesis, diagnosis, management, mitigation, and prevention. *Transfusion.* 2013;53(12):3037-3047.
43. Menis M, Anderson SA, et al. Transfusion-associated circulatory overload (TACO) and potential risk factors among the inpatient US elderly as recorded in Medicare administrative databases during 2011. *Vox Sang.* 2014;106(2):144-152.
44. Alam A, Lin Y, et al. The prevention of transfusion-associated circulatory overload. *Transfus Med.* 2013;27(2):105-112.
45. Blumberg N, Heal JM, et al. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. *Transfusion* 2010;50:2738-44.
46. Park YA, Brecker ME. Bacterial contamination of blood products, in Simon TL, Snyder EL, Solheim BG, et al (ed). *Rossi's Principles of Transfusion Medicine.* Chichester, UK, Wiley-Blackwell, 2009
47. Vidushi, Sidhu M, et al. Evaluation of Incompatible Crossmatch. . *Glob J Trans Med* 2020;5:68-72.
48. College of Physicians and Surgeons of Alberta. Crossmatch Techniques. <http://www.cpsa.ca/accreditation/alqep/transfusion-medicine> (Accessed: 13 August 2013)

49. Swarup CD, Dhot B, Kotwal J, Verma AK. Comparative Study of Blood Cross Matching using Conventional Tube and Gel Method. *MJAFI*, 2008; 64(2): 129–30.
50. Reyneke T. Comparison of the Gel (Diamed-ID Micro Typing System) and Tube Agglutination Cross-Match in Transfusion Medicine. South Africa: Tshwane University of Technology. 2007; 24–6.
51. Namikawa A, Shibuya Y, et al. A Case of ABO-Incompatible Blood Transfusion Treated by Plasma Exchange Therapy and Continuous Hemodiafiltration. *Clin Exp Neph.* 2018; 7: 114-120
  
52. Purwati D, Rofinda Z.D., Husni. Karakteristik Pasien Transfusi Darah dengan Inkompatibilitas Crossmatch di UTD RSUP M. Djamil Padang. Available from : <http://jurnal.fk.unand.ac.id>. Accessed by : 2020.
53. Musumari PM, Mbikay SM. Symptoms of acute transfusion reactions at a general referral hospital in Kinshasa, Democratic Republic of Congo: a cross-sectional study. *BMJ Open* 2021;11.
54. Irawaty, Rachmawati, Arif.M. Characteristics of Crossmatch Types in Compatibility Testing on Diagnosis and Blood Types using Gel Method. *Indones.J Clin.Path.Lab.* 2016.23(1):36-41
55. Rahajeng E.P., Samad R, Muhiddin R. Identification of Risk Factors Characteristics of Transfusion Reaction. *Indones.J.Clin.Path.Lab.* 2020.26(3):266-271
56. Kumar R, Gupta M, et al. Acute Transfusion Reaction (ATRs) in Intensive Care Unit (ICU) : A Retrospective Study. *J.Clin Diagn Res.* 2014. 2(82):127-129.
57. Hatayama Y, Matsumoto S, et al. Analysis of Acute Transfusion Reactions and Their Occurrence Times. *Yon Act Med.* 2018.61:087-090
58. Ruwiyanti E. Profil Hasil Pemeriksaan Crossmatching Incompatible pada Pasien dengan Metode Gel Test. *J Lab Med.* 2021; 2(1): 42-45
59. Arslan O, Senol H, et al. The Role of ABO Incompatibility in Allogeneic Peripheral Blood Stem Cell Transplantation. *Turk J Haematol.* 2002;19(3): 401-409

60. Boukhari R, Breiman A. ABO Blood Group Incompatibility Protect Against SARS-CoV-2 Transmission. *Fro I Microbiol.* 2022
61. Rahim R, Varghese S, et al. Study on Acute Transfusion Related Adverse Reactions in Surgery Department. *Int. J Res Med Sci.* 2021;9(5) :1381-1387
62. Vaithy K, Mathialagan J. Analysis of Patterns of Adverse Transfusion Reactions and Management: A Novel Initiative Toward Hemovigilance in A Teaching Hospital of South India. *J Lab Phys.* 2020;12 :133-140.
63. Lubart E, Segal R, et al. Blood Transfusion Reactions in Elderly Patients Hospitalized in a Multilevel Geriatric Hospital. *J Aging Res.* 2014.
64. Almeida P, Bernarda L. Hemovigilance and Patient Safety : Analysis of Immediate Transfusion Reactions in Elderly. *Rev Bras Enf.* 2020.
65. Fatmasari L, Laili, N.H. Gambaran Kasus Inkompabil Mayor pada Permintaan Darah *Packed Red Cell* (PRC) di Unit Donor Darah PMI Kota Surakarta pada Bulan Januari-Maret. *Avicenna: Journal of Health Research.* 2020; (4) :15-23
66. Chung Y, Ko H, et al. Choice of ABO Group for Blood Component Transfusion in ABO Incompatible Solid Organ Transplantation: A Questionnaire Survey in Korea and Guideline Proposal. *Ann Lab Med.* 2022;42(1): 105-109
67. Vaezi M, Dameshghi, D et al. ABO Incompatibility and Hematopoietic Stem Cell Transplantation Outcomes. *Int J Hem-Onc Stem Cell Res.* 2016;11(2): 1-5
68. Janatpour K, Kalmin N, et al. Clinical Outcomes of ABO Incompatible RBC Transfusion. *Am J Clin Path.* 2008; 129: 276-281

LAMPIRAN

Lampiran I. Form Rekam Medik Transfusi Pasien

Rekam Medik ~~Reaksi~~ Transfusi

No. Reg :  
Nama :  
Umur :  
Jenis Kelamin :  
Reaksi Silang :

Unit ke	I	II	III	IV	V	VI
Komponen						
No. Seri						
Jam Mulai						
Jam Selesai						
<del>Reaksi Transfusi</del>						

~~Nh : Reaksi Transfusi A : gatal dan kemerahan; B : demam , C : sesak napas, D: Penurunan Kesadaran ; E : Lainnya.....~~

Tanda-Tanda Vital Pre Transfusi:

TD :                      N :                      S :                      P :

Tanda-Tanda Vital Post Transfusi

TD :                      N :                      S :                      P :

Dokter  
(dr.                      )

Paramedis  
(                      )

## Lampiran II. Rekomendasi Persetujuan Etik



### REKOMENDASI PERSETUJUAN ETIK

Nomor : 636/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 5 Oktober 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21090547	No Sponsor Protokol	
Peneliti Utama	<b>dr. A. Idfa Muidah Idham,S.Ked</b>	Sponsor	
Judul Peneliti	Gambaran Klinis Reaksi Transfusi pada Pemberian Berbagai Komponen Darah di Kota Makassar		
No Versi Protokol	2	Tanggal Versi	<b>28 September 2021</b>
No Versi PSP	2	Tanggal Versi	<b>28 September 2021</b>
Tempat Penelitian	RS Universitas Hasanuddin dan RS Jejaring di Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 5 Oktober 2021 sampai 5 Oktober 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>	Tanda tangan	

**Kewajiban Peneliti Utama:**

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan